Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 5/20 | 0.39 |
| ▸ | CA2 | P00918 | 5/20 | 0.39 |
| ▸ | CA9 | Q16790 | 5/20 | 0.39 |
| ▸ | CA4 | P22748 | 4/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.38 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2418102 | 1.00 | REN (0.42) | RENCA1CA2CA9CA4 | |
| SCHEMBL15005734 | 1.00 | REN (0.42) | RENCA1CA2CA9CA4 | |
| Hydrochloric Acid SCHEMBL3775320 | 0.98 | REN (0.41) | RENCA1CA2CA9CA4 | |
| Hydrochloric Acid SCHEMBL1162062 | 0.98 | REN (0.41) | RENCA1CA2CA9CA4 | |
| Hydrochloric Acid SCHEMBL3776345 | 0.98 | REN (0.41) | RENCA1CA2CA9CA4 | |
| Benzene SCHEMBL27722875 | 0.92 | REN (0.43) | RENCA1CA2CA9CA4 | |
| Benzene SCHEMBL27743577 | 0.92 | REN (0.43) | RENCA1CA2CA9CA4 | |
| SCHEMBL15825441 | 0.89 | REN (0.36) | RENCA1CA2CA9CA4 | |
| SCHEMBL18788466 | 0.85 | CA1 (0.52) | RENCA1CA2CA9CA4 | |
| SCHEMBL21824741 | 0.85 | CA1 (0.52) | RENCA1CA2CA9CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 181 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104080335-A | Certain chemical entities, compositions, and methods | QIAN XIANGPING | 2014-10-01 | — | — | CN | claimed |
| US-20140273458-A1 | Chemical Mechanical Planarization for Tungsten-Containing Substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-18 | — | — | US | claimed |
| CN-102656179-A | Bufalin derivatives, pharmaceutical compositions and uses thereof | SUZHOU NEUPHARMA CO LTD | 2012-09-05 | — | — | CN | claimed |
| WO-2026090411-A1 | BRM AND BRG1 TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | PRELUDE THERAPEUTICS INCORPORATED (US) | 2026-04-30 | — | — | WO | disclosed |
| WO-2025080631-A1 | PROCESS FOR MAKING A KRAS G12C INHIBITOR | ELI LILLY AND COMPANY (US) | 2025-04-17 | — | — | WO | disclosed |
| WO-2024259171-A9 | KEAP1 INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. (US) | 2025-01-23 | — | — | WO | disclosed |
| WO-2024259171-A2 | KEAP1 INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. (US) | 2024-12-19 | — | — | WO | disclosed |
| EP-4419527-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | Artios Pharma Limited (GB) | 2024-08-28 | — | — | EP | disclosed |
| US-12037346-B2 | Amino-substituted heteroaryls for treating cancers with EGFR mutations | NUVALENT, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20240190868-A1 | SOS1 INHIBITORS | ACERAND THERAPEUTICS (HONG KONG) LIMITED (HK) | 2024-06-13 | — | — | US | disclosed |
| EP-4378938-A1 | NOVEL PARP7 INHIBITOR AND USE THEREOF | Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. (CN) | 2024-06-05 | — | — | EP | disclosed |
| US-20090170861-A1 | Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors | SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. | 2009-07-02 | — | — | US | disclosed |
| US-20090023746-A1 | COMPOUNDS AND THEIR USES 707 | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | disclosed |
| WO-2008115381-A1 | PYRIDAZINONE DERIVATIVES USEFUL AS GLUCAN SYNTHASE INHIBITORS | SCHERING CORPORATION (US) | 2008-09-25 | — | — | WO | disclosed |
| US-20070088039-A1 | Hexahydroimidazopyrazin-3-one compounds useful as modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-19 | — | — | US | disclosed |
| US-6492355-B1 | Adamantane derivatives | ASTRAZENECA AB (SE) | 2002-12-10 | — | — | US | disclosed |
| EP-1171432-A1 | ADAMANTANE DERIVATIVES | AstraZeneca AB (SE) | 2002-01-16 | — | — | EP | disclosed |
| WO-2000061569-A1 | ADAMANTANE DERIVATIVES | ASTRAZENECA AB (SE) | 2000-10-19 | — | — | WO | disclosed |
| US-4943578-A | ANALGESICS; CEREBRAL ANTIISCHEMIC AGENTS | GLAXO GROUP LIMITED (GB) | 1990-07-24 | — | — | US | disclosed |
| EP-0343900-A2 | Piperazine compounds | GLAXO GROUP LIMITED (GB) | 1989-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037346-B2 | Amino-substituted heteroaryls for treating cancers with EGFR mutations | EGFR, ERBB2, ERBB3 | REN 1091/4885CA1 4808/4885CA2 3966/4885 |
| US-20090170861-A1 | Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors | MAN2A1, GYS2, MANBA | REN 3431/4885CA1 4563/4885CA2 3206/4885 |
| US-20090023746-A1 | COMPOUNDS AND THEIR USES 707 | CYP3A7, UGT1A7, UGT2B7 | REN 163/4885CA1 4171/4885CA2 3352/4885 |
| US-20240190868-A1 | SOS1 INHIBITORS | SOS1, SOS2, SOST | REN 1694/4885CA1 3381/4885CA2 3341/4885 |
| US-20070088039-A1 | Hexahydroimidazopyrazin-3-one compounds useful as modulators of androgen receptor function | AR, FSHR, NR5A1 | REN 536/4885CA1 4595/4885CA2 3171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.